48 results about "Low insulin" patented technology

Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.

The invention discloses application of ginseng pectin in prolonging life, and belongs to the technical field of biological medicine. Ginseng pectin and insulin interact with each other, so that the combination process of insulin and a receptor is inhibited, and the activity of an insulin / IGF-1 signal channel is reduced to achieve the effect of prolonging the service life. The low (demethyl) esterified HG structural domain in the ginseng pectin is a key structure for prolonging the life, and is beneficial to the development and application of the pectin in the fields of life-prolonging health care products and functional foods.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

To provide modified or polymer conjugated MetAP2 inhibitors.SOLUTION: The present invention relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.SELECTED DRAWING: Figure 1

The invention discloses application of oxidized berberine and berberrubine in treatment of diabetic osteoporosis, and belongs to the technical field of biological medicine. Researches find that both oxidized berberine and berberrubine have the effect of treating diabetic osteoporosis, and can significantly improve the femur microstructure of a diabetic osteoporosis model animal, so that the femur microstructure recovers to a normal level; the blood glucose clearing capacity can be improved, the insulin resistance index is reduced, and the insulin signal channel function is recovered; the oxidative stress state of diabetic osteoporosis model animals can be relieved, the proinflammatory factor level is reduced, and the anti-inflammatory and anti-oxidation effects are achieved. The invention provides a new scheme and data support for the treatment of diabetic osteoporosis, has better curative effect, safety and economy than the prior art, and has important clinical transformation value.

The embodiment of the invention provides a pancreas islet differentiation method and equipment for microencapsulated induced pluripotent stem cells, and relates to the field of stem cell differentiation. In order to solve the problems of low differentiation efficiency, low insulin secretion function and immunological rejection after transplantation of the two-dimensional cultured iPSC, a method for inducing the iPSC into the islet cells under a three-dimensional condition is constructed, the differentiation efficiency and the functions of the islet cells are improved, immune isolation transplantation can be directly performed after differentiation, and meanwhile, new equipment is constructed. The structure is beneficial to improving the mass transfer efficiency in the induction process, and large-scale and accurate condition control can be realized. The preparation method comprises the following steps: S1, mixing iPSC with a sodium alginate solution to form calcium alginate microspheres containing the iPSC; s2, culturing the iPSC in the calcium alginate microspheres obtained in the step S1 into a cell cluster; and S3, performing stage induced differentiation on the cell cluster obtained in the step S2 to obtain the endocrine cell cluster.

The invention relates to a small-dose automatic metering, subpackaging and storing device and a control method thereof, and relates to the technical field of medical medication configuration and intravenous infusion dosing assistance. The intelligent metering injection unit is arranged in the shell and is used for fixedly mounting a disposable syringe; the piston displacement detection assembly is used for detecting piston displacement in real time; the piston driving and locking mechanism is used for driving the piston of the disposable syringe to automatically shift and be locked at a target dose position; the main control module is used for calculating the actual dose according to the piston displacement; wherein the intelligent metering injection unit provides axial guidance for the disposable syringe, the main control module controls the piston driving and locking mechanism according to the actual dose calculated by the piston displacement detection assembly, and closed-loop metering is achieved. High-precision control over insulin small-dose intravenous dosing can be achieved, the pollution risk caused by pumpback or repeated puncture is avoided, and the actual use loss of insulin injection is reduced on the whole.

The invention discloses an application of TAS2R14 in regulation and control of ADAMTS1 (adenosine monophosphate-adenosine monophosphate) in treatment of insulin resistance. Specifically, the invention provides application of TAS2R14 protein, mRNA or an expression vector thereof, the TAS2R14 protein, the mRNA or the expression vector thereof are used for preparing a preparation or a composition, and the preparation or the composition is used for (a) relieving oxidative stress; (b) reducing insulin resistance (IR). The preparation or composition of the invention effectively reduces insulin resistance and oxidative stress.

The invention is applicable to the technical field of biological medicines, provides application of ophiopogon japonicus borneol glycoside in preparation of a medicine for preventing and treating gestational metabolic diseases, and aims to solve the technical problems that the conventional medicine is limited in use during pregnancy, and the curative effect and the safety are difficult to take into account. According to verification of multi-model systems such as animals, cells and human-derived trophoblast organs, it is found that ophiopogon japonicus borneol glycoside can significantly improve gestational glycometabolism disorder, improve insulin sensitivity and reduce insulin resistance, and therefore effective intervention on gestational diabetes mellitus is achieved. As a natural component derived from the Zhejiang radix ophiopogonis, the radix ophiopogonis borneol glycoside has definite pharmacological activity and excellent safety, and the Zhejiang radix ophiopogonis is listed in a national homology of medicine and food, so that reliable safety guarantee is provided for use during pregnancy.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

The invention relates to a nutritional composition. The nutritional composition consists of fucosyllactose, neutral non-fucosyllactose and sialic acid lactose. According to the nutritional composition disclosed by the invention, by additionally supplementing the nutritional composition in daily diet, the insulin sensitivity is further improved and / or the insulin resistance is reduced, so that a synergistic effect is achieved, and the blood glucose homeostasis of pregnant women is improved.

The invention belongs to the technical field of medicines, and discloses synthesis and application of polycholic acid-short chain fatty acid with a novel structure. The polymer is formed by connecting polycholic acid (as a main chain) with one or more short-chain fatty acids through covalent bonds. The polycholic acid is introduced as a skeleton structure of the polymer and the short-chain fatty acid is introduced as a side chain group, so that the functional polymer with biological activity is constructed. The invention also provides a nano-drug prepared by taking the polymer as a carrier. The nano-drug has good biocompatibility and drug loading capacity, effectively improves the effects of losing weight, reducing fat and relieving liver inflammation, effectively relieves liver fibrosis and aging, can enhance the fatty liver treatment effect and further reduce insulin resistance, and has wide clinical application prospects.

Disclosed herein are methods and agents for decreasing insulin resistance and metformin resistance by modulating insulin receptor condensates. Also disclosed are methods of screening for agents to decrease insulin resistance.

Disclosed herein is a method for promoting insulin sensitivity in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising an monocarboxylate transporter 1 (MCT1) inhibitor. For example, the subject can have or be at risk of developing a metabolic disorder characterized by high blood glucose and low insulin levels, e.g., type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and atherosclerosis. The subject can also have been diagnosed with cancer cachexia or with a cancer, such as a solid tumor or lymphoma.

The present disclosure relates to a composition containing parsnip extract as an active ingredient which reduces the downregulation of tight junction protein expression, promote the proliferation of beneficial intestinal bacteria, improve the intestinal environment such as maintaining a slightly acidic intestinal environment, and have effects such as reducing intestinal permeability. Therefore, the composition may improve intestinal health and prevent, treat, or improve leaky gut syndrome, and may be used as a material for foods, feeds, pharmaceuticals, or quasi-drugs. Additionally, the composition may have body fat reduction and weight loss activities, reduce the protein expression of lipid metabolism-related factors such as ACC, FAS, SREBP1, ChREBP, G6PD, or C / EBPα, and have effects such as reducing liver weight, reducing blood sugar, reducing ALT or AST levels, reducing insulin resistance, and reducing extent of liver damage. Therefore, the composition may prevent, treat, or improve obesity or a metabolic disease.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

The present invention relates to a composition effective in treating diabetes and dyslipidemia prepared according to the solid lipid nanotechnology from two natural phytochemical active ingredients: cinnamonaldehyde extracted from the Vietnamese cinnamon and berberine as a bioactive compound extracted from several plants, including a group of shrubs called Berberis. Via testing, all of the composition of the present invention has shown to have low toxicity and great bioavailability, reduced insulin resistance that allows the sugar level in blood to more effectively induce reduction of insulin, hyperglycolysis that aids the body in cellular sugar decomposition, reduced sugar production in the liver, carbohydrate decomposition slowed down in the intestines, and an increasing in the number of beneficial microbes in the intestines. The composition is effective in reducing the total cholesterol level (TC), and non-HDL-cholesterol, and has a tendency to reduce TG level.

The present disclosure relates to antibodies or antigen-binding fragments thereof that bind specifically to the glucagon-like peptide 1 receptor (GLP1R) protein, and methods of use thereof. In various embodiments, the antibodies or antigen-binding fragments thereof are fully human antibodies that bind to GLP1R. In some embodiments, the antibodies or antigen-binding fragments thereof are useful for attenuating GLP1R activity, thus providing a means of treating, preventing, or alleviating a disease, disorder or condition associated with GLP1R in humans. In some embodiments, the antibodies or antigen-binding fragments thereof elevate glucose levels when administered to a subject and thereby treat hypoglycemia, such as post-bariatric hypoglycemia (PBH), by attenuating insulin secretion from pancreatic beta cells and decreasing insulin expression.

The present invention discloses the application of 1,4-Methylimidazoleacetic acid in the preparation of drugs for preventing and treating obesity, and belongs to the field of biomedical technology. The present invention verifies through animal experiments that 1,4-Methylimidazoleacetic acid can improve the glucose tolerance of obese mice induced by a high-fat diet and reduce the level of insulin resistance; and 1,4-Methylimidazoleacetic acid can significantly reduce lipid deposition and lipid droplet formation in liver tissue, and can also reduce fat mass and the expression level of obesity-related proteins, thereby improving the related symptoms of obesity.

The application is a bifunctional cyclic peptide which reduces insulin and does not increase blood sugar but appropriately reduces blood sugar, and belongs to the technical field of biological medicine. 52‑69 The cyclic peptide is obtained by in-vitro modification and reformation on the basis of the original linear short peptide COX The application realizes the seemingly contradictory two aspects of functions, i.e. inhibiting insulin secretion while not increasing blood sugar, and even reducing blood sugar, and the mechanism may be that the sensitivity of the tissue to insulin is improved. We call it a bifunctional peptide. The bifunctional peptide can be used for congenital hyperinsulinemia, insulin resistance, high insulin of obese people, etc. Literature reports that the increase of insulin is the cause of obesity, but for a long time, we cannot reduce weight by reducing insulin because the blood sugar will increase after the reduction of insulin, and high blood sugar is more harmful to health. The cyclic peptide realizes the function of reducing insulin while the blood sugar does not increase, but is reduced, which opens up a new way for weight loss of obesity, and the peptide can be conveniently administered orally in addition to injection. The convenience of use is greatly improved.

The application discloses application of Clostridium cellabutyricum YQ-FP-027T in preparation of an agent for improving obesity, and belongs to the technical field of functional microorganisms, wherein the Clostridium cellabutyricum YQ-FP-027T is preserved in the China General Microbiological Culture Collection Center, and has a biological preservation number of CGMCC No.7.715. The Clostridium cellabutyricum YQ-FP-027T is a subtype of Clostridium cellabutyricum and is one of probiotics; it is verified through animal experiments that the Clostridium cellabutyricum YQ-FP-027T probiotic can improve the related symptoms of obesity induced by high-fat diet, such as reducing body weight, improving glucose tolerance and reducing insulin resistance level.

A method allows people to not compromise on the taste and flavor of sugar-containing foods and beverages, while reducing the net effect of the sugar in the body. The method may include oral consumption of the enzyme alternansucrase to convert up to 90% of consumed sucrose and other carbohydrates into a carbohydrate complex of undigestible or slowly digestible α-1, 3 and α-1, 6 glucan fibers in the gastrointestinal tract. These glucan fibers have the properties of dietary fibers and a degree of polymerization ranging from 3 to greater than 100. The methods may aid in glucose control, reduce insulin resistance and support healthy glucose homeostasis in diabetic and pre-diabetic conditions. It may promote healthy gut bacteria and improve bowel movements to benefit overall digestive health. It may also be applied to obesity control by reducing blood glucose and, through the production of fiber, blood lipid levels, which supports cardiovascular health.

The application discloses a uORF element for regulating chicken insulin receptor expression and application thereof, belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown in any one of SEQ ID NO. 1-2; the application comprises any one of the following: (1) regulating the expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) being applied to genetic breeding of chickens, and the genetic breeding is breeding of meat chickens with reduced insulin resistance; (3) application in preparation of a reagent for regulating the expression of chicken insulin receptors. The application can regulate the expression level of INSR, improve insulin sensitivity, and provide material support for research on the mechanism of insulin in regulating blood glucose.

The present invention discloses a recombinant insulin gene containing a furin protease cleavage site. The sense strand of the oligonucleotide sequence of the recombinant insulin gene containing the furin protease cleavage site is shown as SEQ ID NO:1, and its antisense strand sequence is shown as SEQ ID NO:2. The present invention also discloses the construction methods and applications of the IRES-hINS recombinant gene, expression cassette, recombinant vector, recombinant cell, lentivirus and its recombinant vector. The present invention also discloses the application of the recombinant gene, etc. in recombinant insulin-related therapeutic drugs. The IRES-hINS sequence designed by the present invention can respond to changes in blood glucose concentration in the culture medium after transfection of cells, thereby increasing or decreasing the synthesis level of insulin, which is of great significance for the treatment of diabetes.

Provided is use of scavenger receptor class A member 3 or a reagent increasing the expression of scavenger receptor class A member 3 in preparing a hypoglycemic product. By means of overexpressing a human-derived SR-A3 gene in hamsters, it was found that the overexpression of the human-derived SR-A3 gene can reduce the plasma glucose concentration, decrease the plasma insulin concentration, improve glucose tolerance, enhance insulin sensitivity, reduce insulin resistance, lower the expression of gluconeogenesis-related genes, and inhibit the activation of the AKT signaling pathway. The present application provides a new target and a new strategy for the precise treatment of patients with hyperglycemia.

The invention belongs to the technical field of fermented food, and particularly relates to a fermented sea-buckthorn beverage as well as a preparation method and application thereof. The fermented hippophae rhamnoides beverage prepared by fermenting the hippophae rhamnoides juice with the volume percentage content of 10%-40% by using the lactobacillus bulgaricus LN6 has obvious capabilities of reducing blood sugar and regulating and controlling blood fat metabolism. Animal experiments show that the fermented sea-buckthorn beverage can improve the symptoms of type II diabetes mellitus, improve the blood sugar level of mice, reduce the serum insulin level, improve the glucagon-like peptide-1 (GLP-1) level and reduce insulin resistance when being used for intragastric administration of type II diabetes mellitus mice. Meanwhile, the fermented hippophae rhamnoides fruit beverage can also recover liver tissue damage and improve abnormal blood lipid metabolism.

The invention discloses an application of GPR110 as a therapeutic target of type 2 diabetes mellitus. The application discovers that the GPR110 gene is used as a therapeutic target of type 2 diabetes for the first time, and provides application of adenovirus-mediated GPR110 gene overexpression in preparation of drugs for treating type 2 diabetes. In an adult type 2 diabetes mouse model db / db, through caudal vein injection of adenovirus-mediated GPR110 overexpression, it is found that the type 2 diabetes related symptoms are significantly improved. The blood glucose level and the fasting blood glucose level are obviously reduced, and an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved. In addition, a decrease in serum insulin level prompts a reduction in pancreatic islet function burden. The results show that the adenovirus-mediated GPR110 overexpression can effectively improve the metabolic disorder of mice with type 2 diabetes mellitus, and a new intervention method and means are provided for the treatment of the type 2 diabetes mellitus.